In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Akshay Peer, co-founder and Senior Vice President of Products at TrakCel.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Akshay, covering:
- How the development of a patent led him into the CGT space—years before it was a market
- The founding story of TrakCel and getting GSK as an anchor client to support early iterations of its custom solution
- Fresh-in, frozen-out… just one of the variations of biospecimens to product in the crazy complex CGT supply chain
- Standardizing, streamlining, and harmonizing will become the de facto software choice for the avalanche of CGTs predicted to be approved by 2030
- The decision to seek strategic investors (instead of financial investors) and the advantages it has brought to TrakCel
Akshay is a co-founder and currently serves as the Senior vice president of Product at TrakCel. Before this, he worked as the Business Development Lead for TrakCel for 8 years, from 2012 to 2018. He then took a break and worked as the CGT lead for Bluecrux.
After a two-year hiatus, Akshay rejoined TrakCel’s team in September 2023 as the new head of product. He is an expert in software solutions to address the challenges of scaling cell and gene therapy products. Akshay has worked with companies developing autologous, allogeneic, CRISPR Cas-9, and other technology-based products.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!